Microchip Biotechnology: Clinical Trial Application for NW001 Injection Accepted

Microchip Biotech Announcement: The company's clinical trial application for the injectable NW001, developed in collaboration with Chengdu Microchip New Domain Biotechnology Co., Ltd. for the treatment of advanced malignant tumors, has recently been accepted by the Center for Drug Evaluation of the National Medical Products Administration, with the acceptance number CXSL2600833 and acceptance date of August 5, 2026.